Lund, 6th October, 2017. SenzaGen (Nasdaq First North: SENZA) announces today that all laboratory elements in the validation of GARDskin have been completed according to plan. After data processing and […]
THIS PRESS RELEASE WAS ORIGINALLY RELEASED IN SWEDISH FOR THE SWEDISH MARKET AND HAS LATER BEEN TRANLSATED TO ENGLISH FOR GENERAL AWARENESS ON THE GLOBAL MARKET Trading in SenzaGen AB’s […]
THIS PRESS RELEASE WAS ORIGINALLY RELEASED IN SWEDISH FOR THE SWEDISH MARKET AND HAS LATER BEEN TRANLSATED TO ENGLISH FOR GENERAL AWARENESS ON THE GLOBAL MARKET SenzaGen AB (“SenzaGen” or […]
THIS PRESS RELEASE WAS ORIGINALLY RELEASED IN SWEDISH FOR THE SWEDISH MARKET AND HAS LATER BEEN TRANLSATED TO ENGLISH FOR GENERAL AWARENESS ON THE GLOBAL MARKET The offer of shares […]
Welcome to SenzaGen Henrik Appelgren! Henrik has started his position as Chief Scientific Officer with us here at SenzaGen this week. Henrik is a biologist with a PhD in genetic […]
SenzaGen new Chief Scientific officer Hernik Appelgren will give a presentation on 21st century testing for skin sensitisation and updates on application of the GARD platform at The 53rd European […]
THIS PRESS RELEASE WAS ORIGINALLY RELEASED IN SWEDISH FOR THE SWEDISH MARKET AND HAS LATER BEEN TRANLSATED TO ENGLISH FOR GENERAL AWARENESS ON THE GLOBAL MARKET. NOT FOR PUBLICATION, DISTRIBUTION […]
By Lhasa Donna Macmillan, Henrik Johansson, Olivia Larne, Malin Lindstedt 1. Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS 2. SenzaGen, Lund, Sweden 3. Lund University, Lund, Sweden […]
Welcome to SenzaGen Anna Chérouvrier Hansson! Anna has started her position as Chief Commercial Officer with us here at SenzaGen this week. Anna comes from Camurus, a pharmaceutical company developing […]
Möt Andy Forreryd från Lunds Universitet och Angelica Johansson från SenzaGen i Forska Utan Djurförsöks event 6 och 7 Juli. Under två seminarier berättar Andy om forskningen bakom GARD. Det […]
